Bold Therapeutics has reported that its first-in-class oncology and antiviral therapeutic, BOLD-100, consistently reduced viral concentrations in several variants of Covid-19, including the B.1.1.7 variant originally identified in the UK.

The company announced the robust preclinical efficacy data of BOLD-100 in a new in vitro research completed by collaborators at the University of British Columbia and Western University.

The latest work expands upon previous research demonstrating that the antiviral therapeutic has strong antiviral activity against the disease in a range of preclinical in vitro models.

To enhance outcomes in Covid-19 patients, Bold Therapeutics continues to advance BOLD-100 as a versatile therapeutic.

Bold Therapeutics noted that the broad antiviral mechanism-of-action of BOLD-100 appears to be unaffected by viral mutations.

It is capable of selectively inhibiting stress-induced upregulation of master chaperone protein GRP78 which plays a vital role in replication of virus.

More than 200 academic articles have identified GRP78 as a potentially attractive antiviral target.

The company, which has generated additional efficacy and safety data, is currently completing in vivo studies of BOLD-100.

It also continues to enrol patients in its Phase Ib study of the antiviral therapeutic for treating advanced gastrointestinal cancers.

More than 50 cancer patients received treatment with BOLD-100, suggesting that it is generally safe and well-tolerated. It is a clinical-stage product and has regulatory clearance in both Canada and the US to initiate clinical trials.

In December 2020, National Research Council of Canada Industrial Research Assistance Program selected Bold Therapeutics for Covid-19 funding and support.

Other companies that received the funding are JN Nova Pharma, Laurent Pharmaceuticals, and Qu Biologics.